Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Dunlop

Showing results (61-70 of 99) with videos related to

Pageof 10
Sort By:
Assay and Drug Development Technologies|January 27, 2005
Validation of an atomic absorption rubidium ion efflux assay for KCNQ/M-channels using the ion Channel Reader 8000Kewei Wang, Beal McIlvain, Eugene Tseng, et al.
Psychopharmacology|October 25, 2008
Acid sensing ion channel (ASIC) inhibitors exhibit anxiolytic-like activity in preclinical pharmacological modelsJason M Dwyer, Stacey J Sukoff Rizzo, Sarah J Neal, et al.
Frontiers in Molecular Neuroscience|March 14, 2017
Cytoplasmic Relocalization of TAR DNA-Binding Protein 43 Is Not Sufficient to Reproduce Cellular Pathologies Associated with ALS <i>In vitro</i>Heike J Wobst, Steven S Wesolowski, Jayashree Chadchankar, et al.
Journal of Biomolecular Screening|September 24, 2009
A novel high-throughput screening assay for HCN channel blocker using membrane potential-sensitive dye and FLIPRDmitry V Vasilyev, Qin J Shan, Yan T Lee, et al.
Molecular Therapy. Methods & Clinical Development|March 19, 2021
Inhibition of KDM1A activity restores adult neurogenesis and improves hippocampal memory in a mouse model of Kabuki syndromeLi Zhang, Genay Pilarowski, Emilio Merlo Pich, et al.
Schizophrenia Research|December 20, 2016
Effects of environmental risks and polygenic loading for schizophrenia on cortical thicknessEmma Neilson, Catherine Bois, Jude Gibson, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 12, 2005
WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activityJohn Dunlop, Annmarie L Sabb, Hossein Mazandarani, et al.
Journal of Neurochemistry|October 15, 2013
Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1Gregory C Luerman, Chuong Nguyen, Harry Samaroo, et al.
Molecular Pharmacology|July 15, 2005
Characterization of novel aryl-ether, biaryl, and fluorene aspartic acid and diaminopropionic acid analogs as potent inhibitors of the high-affinity glutamate transporter EAAT2John Dunlop, H Beal McIlvain, Tikva A Carrick, et al.
Assay and Drug Development Technologies|May 18, 2010
Ion channel screening plates: design, construction, and maintenanceScott C Mayer, John A Butera, David J Diller, et al.
Pageof 10

Showing results (61-70 of 99) with videos related to

Sort By:
Pageof 10
Assay and Drug Development Technologies|January 27, 2005
Validation of an atomic absorption rubidium ion efflux assay for KCNQ/M-channels using the ion Channel Reader 8000Kewei Wang, Beal McIlvain, Eugene Tseng, et al.
Psychopharmacology|October 25, 2008
Acid sensing ion channel (ASIC) inhibitors exhibit anxiolytic-like activity in preclinical pharmacological modelsJason M Dwyer, Stacey J Sukoff Rizzo, Sarah J Neal, et al.
Frontiers in Molecular Neuroscience|March 14, 2017
Cytoplasmic Relocalization of TAR DNA-Binding Protein 43 Is Not Sufficient to Reproduce Cellular Pathologies Associated with ALS <i>In vitro</i>Heike J Wobst, Steven S Wesolowski, Jayashree Chadchankar, et al.
Journal of Biomolecular Screening|September 24, 2009
A novel high-throughput screening assay for HCN channel blocker using membrane potential-sensitive dye and FLIPRDmitry V Vasilyev, Qin J Shan, Yan T Lee, et al.
Molecular Therapy. Methods & Clinical Development|March 19, 2021
Inhibition of KDM1A activity restores adult neurogenesis and improves hippocampal memory in a mouse model of Kabuki syndromeLi Zhang, Genay Pilarowski, Emilio Merlo Pich, et al.
Schizophrenia Research|December 20, 2016
Effects of environmental risks and polygenic loading for schizophrenia on cortical thicknessEmma Neilson, Catherine Bois, Jude Gibson, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 12, 2005
WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activityJohn Dunlop, Annmarie L Sabb, Hossein Mazandarani, et al.
Journal of Neurochemistry|October 15, 2013
Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1Gregory C Luerman, Chuong Nguyen, Harry Samaroo, et al.
Molecular Pharmacology|July 15, 2005
Characterization of novel aryl-ether, biaryl, and fluorene aspartic acid and diaminopropionic acid analogs as potent inhibitors of the high-affinity glutamate transporter EAAT2John Dunlop, H Beal McIlvain, Tikva A Carrick, et al.
Assay and Drug Development Technologies|May 18, 2010
Ion channel screening plates: design, construction, and maintenanceScott C Mayer, John A Butera, David J Diller, et al.
Pageof 10